Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy

Highlights • rLaSota/IL2 has an antitumor potency but is not a pathogenic for man and poultry. • rLaSota/IL2 enhanced the anti-tumor effects and improved the surveillance of tumor-bearing mice compared with rLasota. • Tumor-specific CTL responses are significantly stimulated after rLaSota/IL2-treate...

Full description

Saved in:
Bibliographic Details
Published in:Immunology letters 2014-05, Vol.159 (1), p.36-46
Main Authors: Bai, Fuliang, Niu, Zeshan, Tian, Hui, Li, Siming, Lv, Zheng, Zhang, Tianyuan, Ren, Guiping, Li, Deshan
Format: Article
Language:English
Subjects:
Adaptive Immunity
Allergy and Immunology
Animals
Cancer therapy
Carcinoma, Hepatocellular - immunology
Carcinoma, Hepatocellular - mortality
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - therapy
Cell Line, Tumor
Cell Proliferation
Gene Expression
Genetic Engineering
Humans
IL2
Immunologic Memory
Immunotherapy
Immunotherapy - methods
Interleukin-2 - biosynthesis
Interleukin-2 - genetics
Interleukin-2 - immunology
Liver Neoplasms, Experimental - immunology
Liver Neoplasms, Experimental - mortality
Liver Neoplasms, Experimental - pathology
Liver Neoplasms, Experimental - therapy
Melanoma, Experimental - immunology
Melanoma, Experimental - mortality
Melanoma, Experimental - pathology
Melanoma, Experimental - therapy
Mice
NDV
Newcastle disease virus - genetics
Oncolytic therapy
Oncolytic Virotherapy - methods
rLaSota/IL2
Skin Neoplasms - immunology
Skin Neoplasms - mortality
Skin Neoplasms - pathology
Skin Neoplasms - therapy
Survival Analysis
T-Lymphocytes, Cytotoxic - immunology
T-Lymphocytes, Cytotoxic - pathology
T-Lymphocytes, Regulatory - immunology
T-Lymphocytes, Regulatory - pathology
Tumor Burden
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • rLaSota/IL2 has an antitumor potency but is not a pathogenic for man and poultry. • rLaSota/IL2 enhanced the anti-tumor effects and improved the surveillance of tumor-bearing mice compared with rLasota. • Tumor-specific CTL responses are significantly stimulated after rLaSota/IL2-treated in tumor-bearing mice. • CD4+ and CD8+ T cells proliferation and expression of MHC II are increased after treatment with rLaSota/IL2.
ISSN:0165-2478
1879-0542
DOI:10.1016/j.imlet.2014.02.009